A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).

被引：0
|
作者：
Govindan, Ramaswamy
Awad, Mark M.
Gadgeel, Shirish M.
Pachter, Jonathan A.
Patrick, Gloria
Denis, Louis J.
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Henry Ford Canc Inst, Detroit, MI USA
[4] Verastem Inc, Needham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9148
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Pachter, Jonathan A.
    Koustenis, Andrew G.
    Patrick, Gloria
    Denis, Louis J.
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants
    Coma, S.
    Chowdhury, S.
    Musteanu, M.
    Stewart, A.
    Pickard, L.
    Krebs, M.
    Minchom, A.
    Banerji, U.
    Barbacid, M.
    Pachter, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1124 - S1124
  • [3] The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. Prasad
    Prasad, A.
    Jantus-Lewintre, E.
    Ito, M.
    Cardona, A. F.
    Arrieta, O.
    Cao, P.
    Cai, X.
    Xing, B.
    Pedraz-Valdunciel, C.
    Dantes, Z.
    Sullivan, I.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez-Cao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S112 - S112
  • [4] Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
    Zheng, Xinting
    Luo, Jiamin
    Liu, Wei
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    Lin, Lizhu
    DRUGS OF TODAY, 2022, 58 (04) : 175 - 185
  • [5] The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK
    Coma, Silvia
    Musteanu, Monica
    Caffarra, Cristina
    Mira, Alessia
    Patrucco, Enrico
    Dilly, Julien
    Aguirre, Andrew J.
    Barbacid, Mariano
    Ambrogio, Chiara
    Pachter, Jonathan A.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [6] Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK
    Coma, Silvia
    Chowdhury, Sanjib
    Dilly, Julien
    Musteanu, Monica
    Barbacid, Mariano
    Aguirre, Andrew J.
    Pachter, Jonathan A.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. P.
    Prasad, A.
    Vishwanath, P.
    Jantus Lewintre, E.
    Ito, M.
    Cardona Zorrilla, A. F.
    Arrieta Rodriguez, O. G.
    Pedraz-Valdunciel, C.
    Gonzalez Nieto, J.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez Cao, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1188 - S1188
  • [8] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [9] Initial safety, pharmacokinetics, and recommended Phase 2 dose from RAMP 203: A Phase 1/2 study of Avutometinib plus Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer
    Awad, Mark M.
    Goldschmidt, Jerome
    Spira, Alexander I.
    Malhotra, Rajat
    Yorio, Jeffrey T.
    Bhambhani, Vijeta
    Cheng, Yaofeng
    Lee, Pablo S.
    Govindan, Ramaswamy
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [10] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
    Hong, D. S.
    Bang, Y. -J.
    Barlesi, F.
    Durm, G.
    Falchook, G.
    Govindan, R.
    Dy, G.
    Park, K.
    Strickler, J.
    Burns, T.
    Kim, J.
    Ang, A.
    Lipford, J. R.
    Ngarmchamnanrith, G.
    Anderson, A.
    Li, B. T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
12345